An International, Multicenter, Prospective Non-Interventional Study of Real-World Treatment Outcomes in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) treated with Talazoparib and Enzalutamide (TALENZA) First published 20/10/2023 Last updated 26/09/2024 EU PAS number:EUPAS106719 Study Planned